Ensysce Biosciences (ENSCW) Total Current Liabilities (2017 - 2025)

Ensysce Biosciences (ENSCW) has 9 years of Total Current Liabilities data on file, last reported at $4.6 million in Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $4.6 million, up 106.95% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.6 million (up 106.95% YoY), and the FY2025 annual result was $4.6 million, up 106.95% from the prior year.
• Total Current Liabilities grew to $4.6 million in Q4 2025 per ENSCW's latest filing, from $2.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $16.5 million in Q4 2021 and troughed at $319180.0 in Q1 2021.
• A 5-year average of $4.9 million and a median of $3.1 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2021 and 2022: Total Current Liabilities slumped 90.87% in 2021, then surged 2657.66% in 2022.
• A 5-year view of Total Current Liabilities shows it stood at $16.5 million in 2021, then plunged by 42.58% to $9.5 million in 2022, then plunged by 64.78% to $3.3 million in 2023, then slumped by 33.78% to $2.2 million in 2024, then soared by 106.95% to $4.6 million in 2025.
• Business Quant data shows ENSCW's Total Current Liabilities at $4.6 million in Q4 2025, $2.3 million in Q3 2025, and $2.5 million in Q2 2025.